<DOC>
<DOCNO>EP-0646590</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Ferrocenyldiphosphines substituted with fluoroalkyl groups as ligands for homogeneous catalysts
</INVENTION-TITLE>
<CLASSIFICATIONS>C07C21300	C07C20952	B01J3116	C07C20900	C07F1702	B01J3122	B01J3124	C07F1700	C07C21308	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07C	C07C	B01J	C07C	C07F	B01J	B01J	C07F	C07C	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07C213	C07C209	B01J31	C07C209	C07F17	B01J31	B01J31	C07F17	C07C213	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds of the formula I 
<
IMAGE
>
 wherein R1 is C1-C8-alkyl, phenyl or phenyl substituted by 1 to 3 C1-C4-alkyl or C1-C4-alkoxy groups; R2 is a radical of the formula II   
<
IMAGE
>
 wherein R12 is a C1-C5-alkyl which is partly or completely substituted by fluorine; R13 is C1-C4-alkyl, C1-C4-alkoxy, -SiR4R5R6, halogen, - SO3M, -CO2M, -PO3M, -NR7R8 or -[
<
(+)
>
NR7R8R9]X
<
(-)
>
; m is a number from 1 to 3, n is 0 or a number from 1 to 4 and the sum of m+n is 1 to 5; R3, R10 and R11 independently of one another have the same meaning as R2 or independently of one another are C1-C12-alkyl, C5-C12-cycloalkyl, phenyl, C5-C12-cycloalkyl substituted by C1-C4-alkyl or C1-C4-alkoxy, or phenyl substituted by one to three C1-C4-alkyl, C1-C4-alkoxy, -SiR4R5R 6, halogen, -SO3M, -CO2M, -PO3M, -NR7R8 or -[
<
(+)
>
NR7R8R 9]X
<
(-)
>
; R4, R5 and R6 independently of one another are C1-C12-alkyl or phenyl;  R7 and R8 are H, C1-C12-alkyl, phenyl or R7 and R8 together are tetramethylene, pentamethylene or 3-oxa-1,5-pentylene;  R9 is H or C1-C4-alkyl, M is H or an alkali metal, X
<
(-)
>
 is the anion of a monobasic acid, and 
<
*
>
 marks a stereogenic C atom, in the form of their racemates and diastereomers or mixtures of diastereomers. Rhodium and iridium complexes containing these ligands are suitable as homogeneous enantioselective catalysts for the hydrogenation of prochiral compounds having carbon or carbon/heteroatom double bonds.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
NOVARTIS AG
</APPLICANT-NAME>
<APPLICANT-NAME>
NOVARTIS AG
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
SPINDLER FELIX DR
</INVENTOR-NAME>
<INVENTOR-NAME>
SPINDLER, FELIX, DR.
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Compounds of formula I,


wherein R
1
 is C
1
-C
8
-alkyl, phenyl or phenyl which is substituted by 1 to 3 C
1
-C
4
-alkyl or C
1
-C
4
-alkoxy
groups; R
2
 is a radical of formula II


wherein R
12
 is C
1
-C
5
-alkyl which is partially or completely fluorinated;

R
13
 is C
1
-C
4
-alkyl, C
1
-C
4
-alkoxy, -SiR
4
R
5
R
6
, halogen, -SO
3
M, -CO
2
M, -PO
3
M, -NR
7
R
8
 or
-[
⊕
NR
7
R
8
R
9
]X
⊖
;
m is an integer from 1 to 3, n is 0 or an integer from 1 to 4, and the sum of m+n is 1 to 5;
R
3
, R
10
, R
11
, independently of one another, have the same significance as R
2
 or, independently
of one another, are each C
1
-C
12
-alkyl, C
5
-C
12
-cydoalkyl, phenyl, C
1
-C
4
-alkyl- or C
1
-C
4
-alkoxy-substituted
C
5
-C
12
-cycloalkyl, or phenyl which is mono- to tri-substituted by C
1
-C
4
-alkyl, C
1
-C
4
-alkoxy,
-SiR
4
R
5
R
6
, halogen, -SO
3
M, -CO
2
M, -PO
3
M, -NR
7
R
8
 or -[
⊕
NR
7
R
8
R
9
]X
⊖
 ;
R
4
, R
5
 and R
6
, independently of one another, are C
1
-C
12
-alkyl or phenyl;
R
7
 and R
8
 are H, C
1
-C
12
-alkyl or phenyl or
R
7
 and R
8
 taken together are tetramethylene, pentamethylene or 3-oxa-1,5-pentylene;
R
9
 is H or C
1
-C
4
-alkyl,
M is H or an alkali metal, X
⊖
 is the anion of a monobasic acid, and * is a stereogenic carbon
atom, in the form of their racemates and diastereoisomers or mixtures of diastereoisomers,

with the exception of {(R)-1-[(S)-2-(diphenylphosphino)ferrocenyl]}ethyl bis(4-trifluoromethylphenyl)phosphine.
Compounds of formula I according to claim 1, wherein R
1
 as alkyl is linear.
Compounds of formula I according to claim 2, wherein R
1
 is C
1
-C
4
-alkyl. 
Compounds of formula I according to claim 3, wherein R
1
 is methyl or ethyl.
Compounds of formula I according to claim 1, wherein R
1
 is phenyl or phenyl which is
substituted by one or two C
1
-C
4
-alkyl or C
1
-C
4
-alkoxy groups.
Compounds of formula I according to claim 1, wherein R
3
, R
10
 and R
11
 are C
1
-C
8
-alkyl.
Compounds of formula I according to claim 1, wherein R
3
, R
10
 and R
11
 as cycloalkyl
contain 5 to 8 ring carbon atoms.
Compounds of formula I according to claim 7, wherein R
3
, R
10
 and R
11
 as cycloalkyl are
cyclopentyl or cyclohexyl.
Compounds of formula I according to claim 1, wherein R
3
, R
10
 and R
11
 are phenyl,
2-methyl-, 3-methyl-, 4-methyl-, 2- or 4-ethyl-, 2- or 4-isopropyl-, 2- or 4-tert.-butyl-, 2-methoxy-,

3-methoxy-, 4-methoxy-, 2- or 4-ethoxy-, 4-trimethylsilyl-, 2- or 4-fluoro-, 2,4-difluoro-, 2- or 4-chloro-,
2,4-dichloro-, 2,4-dimethyl-, 3,5-dimethyl-, 2-methoxy-4-methyl-, 3,5-dimethyl-4-methoxy-,

3,5-dimethyl-4-(dimethylamino)-, 2- or 4-amino-, 2- or 4-methylamino-, 2- or 4-(dimethylamino)-,
2- or 4-SO
3
H-, 2- or 4-SO
3
Na-, 2- or 4-[
⊕
NH
3
Cl
⊖
]-, 2,4,6-trimethyl-phen-1 -yl or

3,4,5-trimethyl-phen-1-yl.
Compounds of formula I according to claim 1, wherein R
12
 is C
1
-C
3
-perfluoroalkyl.
Compounds of formula I according to claim 1, wherein R
13
 is C
1
-C
4
-alkyl or C
1
-C
4
-alkoxy.
Compounds of formula I according to claim 1, wherein R
12
 is 4-trifluoromethyl or 3,5-bis(trifluoromethyl).
Compounds of formula I according to claim 1, wherein R
3
, R
10
 and R
11
 are identical
substituents and are phenyl, cyclohexyl, tert.-butyl, 2- or 4-methylphen-1-yl, 2- or 4-methoxyphen-1-yl,

2 or 4-(dimethylamino)phen-1-yl, 3,5-dimethyl-4-(dimethylamino)phen-1-yl or 3,5-dimethyl-4-methoxyphen-1-yl. 
Compounds of formula I according to claim 1, wherein R
2
 and R
3
 are identical
substituents and are a radical of formula II, and R
10
 and R
11
 are identical substituents and are
phenyl, cyclohexyl, tert.-butyl, 2- or 4-methylphen-1-yl, 2- or 4-methoxyphen-1-yl, 2 or 4-(dimethylamino)phen-1-yl,

3,5-dimethyl-4-(dimethylamino)phen-1-yl or 3,5-dimethyl-4-methoxyphen-1
-yl.
Compounds of formula I according to claim 1, wherein R
2
 and R
3
 are identical
substituents and are a radical of formula II, R
10
 is phenyl and R
11
 is cyclohexyl, 2- or 4-methylphen-1-yl,
2- or 4-methoxyphen-1-yl, 4-(dimethylamino)phen-1-yl, 3,5-dimethyl-4-(dimethylamino)phen-1

-yl, 3,5-dimethyl-4-methoxyphen-1-yl or 4-tert.-butylphen-1-yl.
Compounds of formula I according to claim 1, wherein R
1
 is methyl, R
2
 and R
3
 are
identical and are a radical of formula II, R
10
 and R
11
 are identical substituents and are phenyl or
cyclohexyl.
Compounds of formula I according to claim 1, wherein R
2
, R
3
, R
10
 and R
11
 are identical
and are a radical of formula II.
Compounds of formula I according to claim 1, wherein R1 is methyl, R
2
, R
3
, R
10
 and R
11

are identical and are a radical of formula II, R
12
 is 4-trifluoromethyl or 3,5-bis(trifluoromethyl)
and n is 0.
Compounds of formula I according to claim 1, wherein R
1
 is methyl, R
2
 and R
3
 are
identical and are a radical of formula II, R
10
 and R
11
 are phenyl, R
12
 is 4-trifluoromethyl or 3,5-bis(trifluoromethyl)
and n is 0.
Compounds of formula I according to claim 1, wherein they are selected from

{(R)-1-[(S)-2-(bis(4-trifluoromethylphenyl)-phosphino)ferrocenyl]}ethyl bis(3,5-dimethylphenyl)phosphine,
{(R)-1-[(S)-2-(bis(4-trifluoromethylphenyl)-phosphino)ferrocenyl]}ethyl-dicyclohexylphosphine,
{(R)-1-[(S)-2-(bis(3,5-bis-(trifluoromethyl)phenyl)phosphino)ferrocenyl]}ethyl bis(3,5-dimethylphenyl)phosphine,
{(R)-1-[(S)-2-(bis(3,5-bis-(trifluoromethyl)phenyl)phosphino)ferrocenyl]}ethyl-diphenylphosphine

or
{(R)-1-[(S)-2-(bis(4-trifluoromethylphenyl)phosphino)ferrocenyl]}ethyl-diphenylphosphine.
Process for the preparation of compounds of formula I according to claim 1, which
comprises

either reacting a compound of formula III


in the presence of an inert solvent, at room temperature or elevated temperature, with a
phosphine of formula IV


HPR
2
R
3

or reacting a compound of formula VII


wherein R
1
, R
10
 and R
11
 are as defined for formula I, in the presence of an inert solvent, at
room temperature or elevated temperature, with a phosphine of formula IV


HPR
2
R
3

wherein R
1
, R
2
, R
3
, R
10
 and R
11
 are as defined in claim 1.
Complexes of formulae V and VI,

[X
1
M
1
YZ]
[X
1
M
1
Y]
⊕
A
1
⊖

wherein X
1
 is two C
2
-C
12
-olefins or one C
5
-C
12
-diene, Z is Cl, Br or I, A
1
⊖
 is the anion of an
oxyacid or of a complex acid, M
1
 is Rh or Ir, and Y is a compound of formula I as claimed in
claim 1.
Complexes according to claim 22, wherein they are a complex of formula VI.
Complexes according to claim 22, wherein X
1
 is two ethylene, 1,5-hexadiene, 1,5-cyclooctadiene
or norbomadiene. 
Complexes according to claim 22, wherein Z is Cl or Br.
Complexes according to claim 22, wherein Z is ClO
4
⊖
, FSO
3
⊖
, CH
3
SO
3
⊖
, CF
3
SO
3
⊖
, BF
4
⊖
,
PF
6
⊖
, SbCl
6
⊖
, AsF
6
⊖
 and SbF
6
⊖
.
Complexes according to claim 22, wherein R
1
 as alkyl is linear.
Complexes according to claim 27, wherein R
1
 is C
1
-C
4
-alkyl.
Complexes according to claim 28, wherein R
1
 is methyl or ethyl.
Complexes according to claim 22, wherein R
1
 is phenyl or phenyl which is substituted
by 1 or 2 C
1
-C
4
-alkyl or C
1
-C
4
-alkoxy groups.
Complexes according to claim 22, wherein R
3
, R
10
 and R
11
 are C
1
-C
8
-alkyl.
Complexes according to claim 22, wherein R
3
, R
10
 and R
11
 as cycloalkyl contain 5 to 8
ring carbon atoms.
Complexes according to claim 32, wherein R
3
, R
10
 and R
11
 as cycloalkyl are cyclopentyl
or cyclohexyl.
Complexes according to claim 22, wherein R
3
, R
10
 and R
11
 are phenyl, 2-methyl-, 3-methyl-,
4-methyl-, 2- or 4-ethyl-, 2- or 4-isopropyl-, 2- or 4-tert.-butyl-, 2-methoxy-, 3-methoxy-,

4-methoxy-, 2- or 4-ethoxy-, 4-trimethylsilyl-, 2- or 4-fluoro-, 2,4-difluoro-, 2- or 4-chloro-, 2,4-dichloro-,
2,4-dimethyl-, 3,5-dimethyl-, 2-methoxy-4-methyl-, 3,5-dimethyl-4-methoxy-, 3,5-dimethyl-4-(dimethylamino)-,

2- or 4-amino-, 2- or 4-methylamino-, 2- or 4-(dimethylamino)-, 2-or
4-SO
3
H-, 2- or 4-SO
3
Na-, 2- or 4-[
⊕
NH
3
Cl
⊖
]-, 2,4,6-trimethyl-phen-1-yl or 3,4,5-trimethylphen-1-yl.
Complexes according to claim 22, wherein R
12
 is C
1
-C
3
-perfluoroalkyl.
Complexes according to claim 22, wherein R
13
 is C
1
-C
4
-alkyl or C
1
-C
4
-alkoxy.
Complexes according to claim 22, wherein R
12
 is 4-trifluoromethyl or 3,5-bis(trifluoromethyl). 
Complexes according to claim 22, wherein R
3
, R
10
 and R
11
 are identical substituents
and are phenyl, cyclohexyl, tert.-butyl, 2- or 4-methylphen-1-yl, 2- or 4-methoxyphen-1-yl, 2 or

4-(dimethylamino)phen-1-yl, 3,5-dimethyl-4-(dimethylamino)phen-1-yl or 3,5-dimethyl-4-methoxyphen-1-yl.
Complexes according to claim 22, wherein R
2
 and R
3
 are identical substituents and are
a radical of formula II, and R
10
 and R
11
 are identical substituents and are phenyl, cyclohexyl,
tert.-butyl, 2- or 4-methylphen-1-yl, 2- or 4-methoxyphen-1-yl, 2 or 4-(dimethylamino)phen-1-yl,

3,5-dimethyl-4-(dimethylamino)phen-1-yl or 3,5-dimethyl-4-methoxyphen-1-yl.
Complexes according to claim 22, wherein R
2
 and R
3
 are identical substituents and are
a radical of formula II, R
10
 is phenyl and R
11
 is cyclohexyl, 2- or 4-methylphen-1-yl, 2- or 4-methoxyphen-1-yl,
4-(dimethylamino)phen-1-yl, 3,5-dimethyl-4-(dimethylamino)phen-1-yl, 3,5-dimethyl-4-methoxyphen-1-yl

or 4-tert.-butylphen-1-yl.
Complexes according to claim 22, wherein R
1
 is methyl, R
2
 and R
3
 are identical and are
a radical of formula II, R
10
 and R
11
 are identical substituents and are phenyl or cyclohexyl.
Complexes according to claim 22, wherein R
2
, R
3
, R
10
 and R
11
 are identical and are a
radical of formula II.
Complexes according to claim 22, wherein R
1
 is methyl, R
2
, R
3
, R
10
 and R
11
 are
identical and are a radical of formula II, R
12
 is 4-trifluoromethyl or 3,5-bis(trifluoromethyl) and n
is 0.
Complexes according to claim 22, wherein R
1
 is methyl, R
2
 and R
3
 are identical and are
a radical of formula II, R
10
 and R
11
 are phenyl, R
12
 is 4-trifluoromethyl or 3,5-bis(trifluoromethyl)
and n is 0.
Complexes according to claim 22, wherein Y is selected from

{(R)-1-[(S)-2-(bis(4-trifluoromethylphenyl)-phosphino)ferrocenyl]}ethyl bis(3,5-dimethylphenyl)phosphine,
{(R)-1-[(S)-2-(bis(4-trifluoromethylphenyl)-phosphino)ferrocenyl]}ethyl-dicyclohexylphosphine,
{(R)-1-[(S)-2-(bis(3,5-bis-(trifluoromethyl)phenyl)phosphino)ferrocenyl]}ethyl bis(3,5-dimethylphenyl)phosphine, 
{(R)-1-[(S)-2-(bis(3,5-bis-(trifluoromethyl)phenyl)phosphino)ferrocenyl]}ethyl-diphenylphosphine

or
{(R)-1-[(S)-2-(bis(4-trifluoromethylphenyl)phosphino)ferrocenyl]}ethyl-diphenylphosphine.
Use of the complexes of formulae V and VI according to claim 22 as homogeneous
catalysts for the asymmetric hydrogenation of prochiral compounds containing carbon double

bonds or carbon/hetero atom double bonds.
Use according to claim 46 for the hydrogenation of unsymmetric carbon double bonds,
ketimines and ketones.
Use according to claim 46 for the hydrogenation of unsymmetric carbon double bonds
with the rhodium complexes of formulae V and VI.
Process for the asymmetric hydrogenation of compounds containing carbon double
bonds or carbon/hetero atom double bonds under homogeneous reaction conditions, which

comprises hydrogenating said compounds in the temperature range from -20 to +80°C and
under a hydrogen pressure of 10
4
 to 10
7
 Pa in the presence of catalytic amounts of a complex
of formulae V or VI according to claim 22.
Process according to claim 49, wherein the hydrogen pressure is from 10
5
 to 6·10
6
 Pa.
Process according to claim 49, wherein the temperature is in the range from -10 to
+50°C.
Process according to claim 49, wherein the amount of catalyst is chosen such that the
molar ratio of compound to be hydrogenated (substrate) to complex of formula V or VI is

100,000 to 20.
Process according to claim 49, wherein the reaction is carried out in the presence of a
solvent.
Process according to claim 49, wherein the solvent is methanol or a mixture of
methanol and benzene or toluene.
</CLAIMS>
</TEXT>
</DOC>
